Our biodistribution studies revealed no accumulation of NIR-sTN58 in healthy organs (e.g. heart and muscle) thus, we expect that sTN58 cytotoxicity will be mostly confined to CD44-overexpressing cancer cells, similar to what occurs with most therapeutic agents targeting proteins that are mainly, but not exclusively, expressed in tumors. This evidence concerns the gene CD44 and cancer.